China Biotech Services Holdings Limited

8037.HK · Hong Kong Stock Exchange · HKD

0,39HKD

−0,03 (−7,14 %)Stand 10. Nov., 7:59

Vortag 0,42

Kennzahlen

Eröffnung
0,40
Vortag
0,42
Tagesspanne
0,375 – 0,40
52 Wochen
0,30 – 1,04
Volumen
75.000
Ø Volumen
439.346
Börsenwert
380,54 Mio. HKD
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
-0,7
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Established in 1996 and based in Causeway Bay, Hong Kong, China Biotech Services Holdings Limited functions as an investment holding company. Its core business involves providing medical laboratory testing and health check services throughout mainland China and Hong Kong. The company organizes its varied operations into five main divisions: Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, and Insurance Brokerage, in addition to other undertakings. Its comprehensive activities include the research, development, manufacturing, and sale of both health-related and pharmaceutical products. The company also offers specialized medical services, such as tumor immune cell therapy, immune cell storage, and health management programs, alongside coordinating healthcare providers. Furthermore, it participates in financial services like securities trading, money lending, and providing insurance brokerage. Its commercial ventures also extend to marketing and distributing a range of wellness products, including health supplements, slimming aids, traditional Chinese medicines, and beauty products, as well as trading pharmaceutical intermediates. Property investment and logistics services round out its operational scope. The company transitioned to its current name in November 2017, having previously been known as Rui Kang Pharmaceutical Group Investments Limited.

CEO
Xiaolin Liu
Mitarbeitende
166
Hauptsitz
Hong Kong, HK
Sektor
Healthcare
Branche
Medical - Diagnostics & Research
Börsengang
17. Juni 2004
Website
cbshhk.com

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.